# Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference

> **NIH NIH R13** · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $74,999

## Abstract

PROJECT SUMMARY
 ANNUAL HVTN TRANSLATIONAL HIV EARLY STAGE INVESTIGATOR (ESI) CONFERENCE
This R13 application requests continued NIH support for four annual conferences for Early Stage Investigators
(ESIs) conducting translational HIV vaccine, co-morbidity, barrier to infection, and cure research with nonhuman
primates (NHPs). The Conference offers an intimate setting where ESIs build skills, knowledge, professional
networks and career development strategies with their peers and senior investigators in the field. Year 1 is
proposed to take place September 28-29, 2020 in Portland, OR, immediately preceding the 38th NHP-AIDS
Symposium, with complementary programming planned. Subsequent meetings will be adjacent to either the
Symposium or HIV Vaccine Trials Network (HVTN) Full Group Meeting, allowing for additional opportunities for
learning, training and networking. Conference topic selection will be guided by a needs assessment from K01
HIV/AIDS Scholars and mentors, an innovative practice used to great effect for the 2017-2019 Conferences.
Agenda development and advising for these Conferences will be led by a diverse, multi-disciplinary group of
experts in the fields at multiple stages in their careers. Attendees at the ESI Conferences will participate in
training and skill-building activities on important translational scientific topics (e.g., state of prevention, vaccine,
therapeutic and cure research; TB and coinfections in the NHP model); mentoring opportunities with senior and
peer investigators (e.g., panel discussions on partnerships and career paths in the field); career development
training (e.g., ESI funding landscape, how to conduct research with HVTN); “Works in Progress” presentations;
and organized networking opportunities with other ESIs and senior investigators (e.g., receptions, randomized
seating). We will fund attendance at these Conferences and the HVTN Full Group Meeting or NHP-AIDS
Symposium for talented ESIs, with priority for underrepresented applicants, and K01 mentors, providing
opportunities for these groups to continue to interact and support translational science. The Conference is open
to all qualified investigators at no cost to attendees. Inclusion of women, underrepresented minorities and
individuals with disabilities will be supported as speakers, attendees and advisors. The Conferences will be
organized by staff at the HVTN, the world’s largest publicly funded collaboration facilitating the development and
testing of vaccines to prevent HIV/AIDS. They will be housed within the existing HVTN Training Program, which
has shown considerable success in supporting investigators at multiple career stages, and which organized
highly meaningful and impactful ESI Conferences from 2017-2019. These conferences fill a critical gap in
scientific knowledge and workforce development by facilitating greater translation of research between preclinical
NHP studies and clinical trials, which will ultimately accelerate progress towa...

## Key facts

- **NIH application ID:** 10015978
- **Project number:** 2R13OD024033-04
- **Recipient organization:** FRED HUTCHINSON CANCER RESEARCH CENTER
- **Principal Investigator:** James G. Kublin
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $74,999
- **Award type:** 2
- **Project period:** 2017-04-07 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10015978

## Citation

> US National Institutes of Health, RePORTER application 10015978, Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference (2R13OD024033-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10015978. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*